17 hours Ago By ABMN Staff
KLP Kapitalforvaltning AS bought a new position in IDEAYA Biosciences, Inc. ( NASDAQ:IDYA – Free Report ) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 14,900 shares of the company’s stock, valued at approximately $383,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of IDEAYA Biosciences by 0.5% in the fourth quarter.
Rhumbline Advisers now owns 113,561 shares of the company’s stock worth $2,919,000 after buying an additional 585 shares during the period. Daiwa Securities Group Inc. increased its holdings in IDEAYA Biosciences by 44.
0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock worth $72,000 after acquiring an additional 853 shares in the last quarter.
Assetmark Inc. increased its holdings in IDEAYA Biosciences by 2.5% in the 4th quarter.
Assetmark Inc. now owns 45,269 shares of the company’s stock worth $1,163,000 after acquiring an additional 1,084 shares in the last quarter. R Squared Ltd bought a new stake in IDEAYA Biosciences during the 4th quarter worth approximately $35,000.
Finally, Handelsbanken Fonder AB lifted its holdings in IDEAYA Biosciences by 8.1% during the fourth quarter. Handelsbanken Fonder AB now owns 25,300 shares of the company’s stock valued at $650,000 after purchasing an additional 1,900 shares in the last quarter.
98.29% of the stock is currently owned by hedge funds and other institutional investors. IDEAYA Biosciences Price Performance NASDAQ:IDYA opened at $14.
71 on Friday. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -4.
46 and a beta of 0.51. IDEAYA Biosciences, Inc.
has a 1 year low of $14.40 and a 1 year high of $44.42.
The stock’s 50 day simple moving average is $20.05 and its two-hundred day simple moving average is $25.19.
Analysts Set New Price Targets Several analysts have recently commented on IDYA shares. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th.
Wedbush reiterated an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th.
Finally, Stephens reiterated an “overweight” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock.
According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.58. Read Our Latest Analysis on IDEAYA Biosciences About IDEAYA Biosciences ( Free Report ) IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. Read More Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc.
( NASDAQ:IDYA – Free Report ). Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
